市場調査レポート

経口腫瘍溶解剤シリーズ:白血病

Oral Oncolytics Series: Leukemia, 2014 - 2024

発行 ROOTS ANALYSIS 商品コード 303594
出版日 ページ情報 英文 139 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
経口腫瘍溶解剤シリーズ:白血病 Oral Oncolytics Series: Leukemia, 2014 - 2024
出版日: 2014年05月21日 ページ情報: 英文 139 Pages
概要

標的療法は生物薬剤産業における主要な焦点領域として急浮上しています。経口標的療法は患者(特に小児・高齢患者)への投与が簡単なことから、多くの医薬品開発企業を惹きつけています。白血病の場合、現在の上市経口薬にはGleevec、Tasigna、Sprycel、Bosulif、Imbruvica および Iclusigなどがあります。

当レポートでは、経口標的型の白血病治療薬市場について、特に現在市販されている、開発中および将来の市場発展が期待できる治療薬に焦点を当てて調査し、規制承認、治療費、販売実績、製品パイプラインおよび産業調査プログラムなどの多様な側面も取り上げ、お届けいたします。

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 白血病
  • 白血病の種類
  • 一般的徴候・症状
  • 発生率と有病率
  • 現在の治療計画

第4章 市場概要

  • 本章の概要
  • 調査範囲
  • 白血病の標的療法市場
  • 白血病の経口標的療法市場
  • パイプライン分析:白血病特有の亜類型別
  • その他の血液悪性腫瘍向け経口標的薬

第5章 白血病の経口標的薬:現在の市場・予測

  • 本章の概要
  • 全体的な市場規模・予測
  • Imatinib (Novartis Pharmaceuticals)
  • Nilotinib (Novartis Pharmaceuticals)
  • Dasatinib (Bristol-Myers Squibb)
  • Bosutinib (Pfizer Inc.)
  • Ponatinib (ARIAD Pharmaceuticals, Inc.)
  • Ibrutinib (Pharmacyclics Inc./ Janssen Pharmaceuticals)
  • Idelalisib (Gilead Sciences, Inc.)
  • Midostaurin (Novartis Pharmaceuticals)
  • ABT-199 / GDC-0199 (Abbott / Roche)
  • IPI - 145 (Infinity Pharmaceuticals / Millennium)

第6章 経口標的治療市場の地域分析

  • 概要
  • 米国は経口標的白血病薬の最大市場
  • 日本
  • 欧州

第7章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第8章 結論

  • 白血病:成人ではまれな疾患だが、子供では最も一般的ながん
  • 白血病用の6つの治療薬、 急性骨髄性白血病(AML)患者用は無い
  • 高い年間治療費:懸案事項、安心のための医療費償還プログラム
  • 差し迫る特許満了にも関わらず、市場はさらに上昇へと向かう
  • 結論

第9章 付録1

第10章 付録2

図表

目次
Product Code: RA10014

Targeted therapeutics is fast emerging as the key focus area in biopharmaceutical industry. Oral targeted therapeutics has attracted many drug developers due to the ease of administration it offers to patients (especially pediatric and geriatric patients). In the case of leukemia, current marketed oral drugs include Gleevec, Tasigna, Sprycel, Bosulif, Imbruvica and Iclusig.

The high price of these drugs still remains a major constraint to the market growth. Further, as leukemia accounts for about 3% of all cancer cases per year, most of the companies are targeting other cancer indications offering a wider market prospective. The oral targeted drugs market is expected to be driven by new generation and new class of inhibitors. Several pharmaceutical companies, both big and small, are looking to capture a share of the leukemia market, where orally delivered drugs are well accepted.

Despite the impending patent expiry of some drugs (especially Gleevec), the market is set to rise after a likely dip in growth rate in the short-term. There are specific opportunities which remain to be tapped in the mid-long term; emerging drug therapies such as third generation tyrosine kinase inhibitors (TKIs), multi kinase inhibitors, FLT3 inhibitors, AKT kinase inhibitors and BTK inhibitors are likely to sustain the interest of drug makers.

Synopsis

The 'Oral Oncolytics Series: Leukemia, 2014 - 2024' report provides an extensive study of the market of oral targeted leukemia drugs, specifically focusing on currently commercialized drugs, those under development and the likely future market evolution. Targeted therapeutics have tremendous potential and the market is expected to grow steadily over the coming few years. The focus of our report is on drugs which target a specific marker / antigen on leukemia cells and are delivered through mouth. The report covers various aspects such as regulatory approvals, treatment cost, historical sales, product pipeline and industry research programs.

With the upcoming patent expiry of some well-known drugs, we have looked at how the market landscape is likely to change in the coming years. In fact, one of the key objectives of this report is to understand the current and future state of the oral targeted leukemia drugs. This is done by analyzing the following:

  • Marketed oral targeted leukemia drugs
  • Products in pipeline
  • Competing technologies and innovations
  • Growing target patient pool

The base year for the report is 2013. The report provides short-mid term and long term forecasts for the period 2014 - 2024. This forecast is supported by detailed research and analysis of drugs (both marketed / pipeline) which we believe will have a far-reaching impact on the market. Owing to the uncertainties associated with drug development and customer adoption trends, we have presented three different market scenarios for each of the drugs studied in this exercise:

  • Conservative Scenario: This represents our most pessimistic view of the success / adoption of each individual drug.
  • Base Scenario: This represents the most-likely success / adoption of respective drugs.
  • Aggressive Scenario: This is the bullish scenario wherein we have been aggressive in terms of the penetration rates of respective drugs and the likely market size.

Example Highlights

  • 1. The market for oral targeted leukemia therapeutics was valued at USD 7,388 million in 2013; CML drugs currently dominate the market.
  • 2. US, with a 40.6% share, is currently the biggest market. According to the Leukemia & Lymphoma Society, there are an estimated 310,046 people living with, or in remission from, leukemia in the US
  • 3. Gleevec, the market leader, has been quite popular amongst patient population. However, its nearing patent expiry (2014, 2015, 2016 in Japan, the US and Europe respectively) will open the space for low cost generics
  • 4. There are several upcoming drugs, with a sizeable number in phase II and phase III clinical trials. Opportunities for drug developers exist in all forms of leukemia.
  • 5. AML has the most extensive pipeline; in addition to tyrosine kinases, hedgehog, JAK, PI3K inhibitors, drug developers are also exploring the use of epigenetic agents such as histone deacetylases (HDAC) and nuclear export inhibitors such as XPO1 inhibitor.
  • 6. Novartis is the most active company in this market, with two marketed drugs and another eight in clinical trials. Specifically, within AML (which currently has no marketed oral drug), Novartis' Midostaurin is expected to have the first mover advantage.

Research Methodology

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Leukemia
  • 3.2. Types Of Leukemia
  • 3.3. Common Signs And Symptoms
  • 3.4. Incidence And Prevalence
  • 3.5. Current Treatment Regimes

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Scope
  • 4.3. Targeted Leukemia Therapeutics Market, 2013
    • 4.3.1. Approved Targeted Leukemia Therapeutics, 2013
    • 4.3.2. Within Leukemia, CML Drugs Dominate the Market
    • 4.3.3. Four Leading Drugs Captured 98% of the Market in 2013
  • 4.4. Oral Targeted Leukemia Therapeutics Market, 2013
  • 4.5. Pipeline Analysis: By Specific Leukemia Sub-Types
    • 4.5.1. Chronic Myeloid Leukemia (CML)
      • 4.5.1.1. A Mature Market; Impending Threat of Patent Expiry
      • 4.5.1.2. Development of Next Generation TKIs
      • 4.5.1.3. Unravelling the Potential of Inhibitors Other Than Tyrosine Kinases
    • 4.5.2. Chronic Lymphocytic Leukemia
      • 4.5.2.1. Gazyva: Successor for Rituxan
      • 4.5.2.2. Rich Pipeline Mainly Focusing on Relapsed / Refractory Population
    • 4.5.3. Acute Myeloid Leukemia
      • 4.5.3.1. A High Opportunity Area
      • 4.5.3.2. Epigenetic Agents and Nuclear Export Inhibitors
    • 4.5.4. Acute Lymphocytic / Lymphoblastic Leukemia (ALL)
      • 4.5.4.1. Most Common Cancer in Children
      • 4.5.4.2. Limited Molecules in Pipeline
  • 4.6. Other Oral Targeted Drugs for Haematological Malignancies

5. ORAL TARGETED LEUKEMIA DRUGS: CURRENT MARKET AND FORECAST

  • 5.1. Chapter Overview
    • 5.1.1. Scope and Limitations
    • 5.1.2. Market Forecast: Assumptions and Methodology
  • 5.2. Overall Market Size and Forecast
    • 5.2.1. Overall Oral Targeted Leukemia Drugs Market Forecast
  • 5.3. Imatinib (Novartis Pharmaceuticals)
    • 5.3.1. History of Development
    • 5.3.2. Approval History
    • 5.3.3. Mechanism of Action
    • 5.3.4. Pricing and Reimbursement
    • 5.3.5. Historical Sales
    • 5.3.6. Launch of Generics in the Market
    • 5.3.7. Withdrawal of Development in PAH
    • 5.3.8. Gleevec Sales Forecast, Short-Mid Term (2014-2018)
    • 5.3.9. Gleevec Sales Forecast, Long Term (2018-2024)
  • 5.4. Nilotinib (Novartis Pharmaceuticals)
    • 5.4.1. Approval History
    • 5.4.2. Mechanism of Action
    • 5.4.3. Tasigna and Gleevec: Novartis' BCR/ABL Franchise
      • 5.4.3.1. Moving Gleevec Patients to Tasigna before Patent Expiry
    • 5.4.4. Treatment Cost
    • 5.4.5. Historical Sales
    • 5.4.6. Active Clinical Trials
    • 5.4.7. Tasigna Sales Forecast, Short-Mid Term (2014-2018)
    • 5.4.8. Tasigna Sales Forecast, Long Term (2018-2024)
  • 5.5. Dasatinib (Bristol-Myers Squibb)
    • 5.5.1. Orphan Drug Designations
    • 5.5.2. Approval History
    • 5.5.3. Mechanism of Action
    • 5.5.4. Pricing and Reimbursement
    • 5.5.5. Historical Sales
    • 5.5.6. Active Clinical Trials
    • 5.5.7. Patent Expiry and Generics
    • 5.5.8. Sprycel Sales Forecast, Short-Mid Term (2014-2018)
    • 5.5.9. Sprycel Sales Forecast, Long Term (2018-2024)
  • 5.6. Bosutinib (Pfizer Inc.)
    • 5.6.1. Approval History
    • 5.6.2. Mechanism of Action
    • 5.6.3. Pricing and Reimbursement
    • 5.6.4. Historical Sales
    • 5.6.5. Ongoing Clinical Trials
      • 5.6.5.1. Partnership With Avillion for First-Line Treatment
    • 5.6.6. Manufacturing
    • 5.6.7. Bosutinib Sales Forecast, Short-Mid Term (2014-2018)
    • 5.6.8. Bosutinib Sales Forecast, Long Term (2018-2024)
  • 5.7. Ponatinib (ARIAD Pharmaceuticals, Inc.)
    • 5.7.1. Approval and Launch History
    • 5.7.2. Mechanism of Action
    • 5.7.3. Setback and Re-launch in the US
    • 5.7.4. Pricing and Reimbursement
    • 5.7.5. Historical Sales
    • 5.7.6. Ongoing Clinical Trials
    • 5.7.7. Manufacturing
    • 5.7.8. Iclusig Sales Forecast, Short-Mid Term (2014-2018)
    • 5.7.9. Iclusig Sales Forecast, Long Term (2018-2024)
  • 5.8. Ibrutinib (Pharmacyclics Inc./ Janssen Pharmaceuticals)
    • 5.8.1. Historical Development
    • 5.8.2. Breakthrough Therapy Designation
    • 5.8.3. Mechanism of Action
    • 5.8.4. Pricing and Reimbursement
    • 5.8.5. Historical Sales
    • 5.8.6. Market Expansion Strategies
    • 5.8.7. Manufacturing of Ibrutinib
    • 5.8.8. Ibrutinib Sales Forecast, Short-Mid Term (2014-2018)
    • 5.8.9. Ibrutinib Sales Forecast, Long Term (2018-2024)
  • 5.9. Idelalisib (Gilead Sciences, Inc.)
    • 5.9.1. History of Development
    • 5.9.2. Mechanism of Action
    • 5.9.3. Another First-in-Class Inhibitor for CLL
    • 5.9.4. Early Termination of Study GS-US-312-0116
    • 5.9.5. Ongoing Clinical Trials
    • 5.9.6. Idealisib Sales Forecast, Short-Mid Term (2014-2018)
    • 5.9.7. Idealisib Sales Forecast, long term (2018-2024)
  • 5.10. Midostaurin (Novartis Pharmaceuticals)
    • 5.10.1. Orphan Drug Designations
    • 5.10.2. Mechanism of Action
    • 5.10.3. First Mover Advantage in the AML Market?
    • 5.10.4. Screening for FLT3 Mutation
    • 5.10.5. Active Clinical Trials
    • 5.10.6. Midostaurin Sales Forecast, Short-Mid Term (2016-2018)
    • 5.10.7. Midostaurin Sales Forecast, Long Term (2018-2024)
  • 5.11. ABT-199 / GDC-0199 (Abbott / Roche)
    • 5.11.1. Mechanism of Action
    • 5.11.2. Screening for a Biomarker
    • 5.11.3. A Temporary Clinical Hold
    • 5.11.4. Active Clinical Trials
    • 5.11.5. ABT-199 Sales Forecast, Long Term (2019-2024)
  • 5.12. IPI - 145 (Infinity Pharmaceuticals / Millennium)
    • 5.12.1. History of Development
    • 5.12.2. Orphan Drug Designation
    • 5.12.3. Mechanism of Action
    • 5.12.4. Impressive Phase I Results Led to Phase III Trials
    • 5.12.5. Active Clinical Trials
    • 5.12.6. IPI-145 Sales Forecast, Long Term (2019-2024)

6. REGIONAL ANALYSIS OF ORAL TARGETED THERAPEUTICS MARKET

  • 6.1. Overview
  • 6.2. US is the Largest Market For Targeted Oral Leukemia Drugs
    • 6.2.1. Epidemiology of Leukemia in the US
    • 6.2.2. Availability and Reimbursement
  • 6.3. Japan
    • 6.3.1. Epidemiology of Leukemia in Japan
    • 6.3.2. Availability and Reimbursement
  • 6.4. Europe
    • 6.4.1. Epidemiology of Leukemia in Europe
    • 6.4.2. France
    • 6.4.3. Germany
    • 6.4.4. United Kingdom

7. SWOT ANALYSIS

  • 7.1. Overview
  • 7.2. Strengths
    • 7.2.1. Ease of Administration
    • 7.2.2. Positive Reimbursement Status in Major Developed Countries
  • 7.3. Weaknesses
    • 7.3.1. Small Patient Pool
    • 7.3.2. High Annual Treatment Cost
  • 7.4. Opportunities
    • 7.4.1. Development of next generation TKIs
    • 7.4.2. Limited Treatment Options for Pediatric Patients at Present
  • 7.5. Threats
    • 7.5.1. Development of Vaccines
    • 7.5.2. Competition from Monoclonal Antibody Therapeutics

8. CONCLUSION

  • 8.1. Leukemia: A Rare Disease in Adults but Most Common Cancer in Children
  • 8.2. Six Drugs for Leukemia, None for AML Group of Patients
  • 8.3. High Annual Treatment Cost: A Concern, Reimbursement Schemes to Relief
  • 8.4. Despite Impending Patent Expiries, Market Set to Rise Further
  • 8.5. Concluding Remarks

9. APPENDIX 1: List of Companies and Organizations

10. APPENDIX 2: Tabulated Data

List of Figures

  • Figure 3.1 Leukemia: Incidence Rate in the US (2013)
  • Figure 3.2 Leukemia: Incidence Rate in the US by Age Group (2006 - 2010)
  • Figure 4.1 Targeted Leukemia Drugs Market, 2013 - Split by Indication (USD Million)
  • Figure 4.2 Targeted Leukemia Drugs Market, 2013 - Split by Leading Drugs (USD Million)
  • Figure 4.3 Oral Targeted Leukemia Drugs Market, 2013 (USD Million)
  • Figure 4.4 Targeted CML Therapeutics Market, 2013 (USD Million) - Split by Leading Drugs
  • Figure 4.5 Oral Targeted CML Drugs, 2014 - Split by Phase of Development
  • Figure 4.6 Targeted CLL Therapeutics Market, 2013 - Split by Leading Drugs (USD Million)
  • Figure 4.7 Oral Targeted CLL Drugs, 2014 - Split by Phase of Development
  • Figure 4.8 Oral Targeted AML Drugs, 2014 - Split by Phase of Development
  • Figure 4.9 Targeted ALL Therapeutics Market, 2013 - Split by Leading Drugs
  • Figure 4.10 Oral Targeted ALL Drugs, 2014 - Split by Phase of Development
  • Figure 5.1 Overall Oral Targeted Leukemia Drugs Market Forecast: Base Scenario (USD Million)
  • Figure 5.2 Gleevec/Glivec Sales, 2005-2013 (USD Million)
  • Figure 5.3 Gleevec/Glivec Sales by Region, 2013 (%)
  • Figure 5.4 Gleevec Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Figure 5.5 Gleevec Sales Forecast, Long Term: Base Scenario (USD Million)
  • Figure 5.6 Novartis BCR/ABL Franchise Sales, 2013 (USD Million)
  • Figure 5.7 Tasigna Sales, 2008-2013 (USD Million)
  • Figure 5.8 Tasigna Sales by Region, 2013 (%)
  • Figure 5.9 Tasigna Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Figure 5.10 Tasigna Sales Forecast, Long Term: Base Scenario (USD Million)
  • Figure 5.11 Sprycel Sales, 2006-2013 (USD Million)
  • Figure 5.12 Sprycel Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Figure 5.13 Sprycel Sales Forecast, Long Term: Base Scenario (USD Million)
  • Figure 5.14 Bosutinib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Figure 5.15 Bosutinib Sales Forecast, Long Term: Base Scenario (USD Million)
  • Figure 5.16 Iclusig Sales, 2013 (USD Million)
  • Figure 5.17 Iclusig Sales Distribution by Region, Q4 2013 (USD Million)
  • Figure 5.18 Iclusig Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Figure 5.19 Iclusig Sales Forecast, Long Term: Base Scenario (USD Million)
  • Figure 5.20 Ibrutinib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Figure 5.21 Ibrutinib Sales Forecast, Long Term: Base Scenario (USD Million)
  • Figure 5.22 Idealisib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Figure 5.23 Idealisib Sales Forecast, Long Term: Base Scenario (USD Million)
  • Figure 5.24 FLT3 Mutation in Acute Myeloid Leukemia Patients (%)
  • Figure 5.25 Midostaurin Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Figure 5.26 Midostaurin Sales Forecast, Long Term: Base Scenario (USD Million)
  • Figure 5.27 ABT-199 Sales Forecast, Long Term: Base Scenario (USD Million)
  • Figure 5.28 IPI-145 Sales Forecast, Long Term: Base Scenario (USD Million)
  • Figure 6.1 Oral Targeted Leukemia Drugs Market - Split by Regions, 2013 (%)
  • Figure 6.2 Prevalence of Leukemia in the US, 2013 (%)
  • Figure 6.3 Incidence of Types of Leukemia in the US, 2013 (%)
  • Figure 6.4 Oral Targeted Leukemia Drugs Market in the US, 2013 - Split by Drugs (USD Million)
  • Figure 6.5 Incidence of Leukemia in Japan, 2012
  • Figure 6.6 Leukemia Incidence: Major EU Countries, 2012
  • Figure 8.1 Oral Targeted Leukemia Drugs Market Forecast (USD Million): Comparative Scenarios

List of Tables

  • Table 4.1 List of Approved Targeted Drugs for ALL, 2013
  • Table 4.2 List of Approved Targeted Drugs for CLL, 2013
  • Table 4.3 List of Approved Targeted Drugs for CML, 2013
  • Table 4.4 Target Kinases for Approved Small Molecule Inhibitors
  • Table 4.5 Comparison of the Marketed Targeted Inhibitors for CML
  • Table 4.6 CML Pipeline: Oral Targeted Drugs, 2014
  • Table 4.7 Comparison of the Marketed Targeted Inhibitors for CLL
  • Table 4.8 Rituximab Biosimilars Under Development, 2014
  • Table 4.9 CLL Pipeline: Oral Targeted Drugs, 2014
  • Table 4.10 AML Pipeline: Oral Targeted Drugs, 2014
  • Table 4.11 Comparison of the Marketed Targeted Inhibitors for ALL
  • Table 4.12 ALL Pipeline: Oral Targeted Drugs, 2014
  • Table 4.13 Some More Oral Targeted Drugs for Leukemia, 2014
  • Table 5.1 Oral Targeted Leukemia Drugs (Phase III and Higher): Current Development Phase and Expected Launch Year
  • Table 5.2 Gleevec: Marketing Approvals
  • Table 5.3 Gleevec: Dosage Regime
  • Table 5.4 Tasigna: Orphan Drug Designation
  • Table 5.5 Tasigna: Marketing Approvals
  • Table 5.6 Tasigna: Treatment Duration and Cost
  • Table 5.7 Tasigna: Clinical Trials and Development Status
  • Table 5.8 Dasatinib: Orphan Drug Designation History
  • Table 5.9 Sprycel: Approval History
  • Table 5.10 Sprycel: Course and Treatment Cost
  • Table 5.11 Sprycel: Clinical Trials and Development Status
  • Table 5.12 Bosulif: Treatment Duration and Cost
  • Table 5.13 Bosulif: Clinical Trials and Development Status
  • Table 5.14 Ponatinib: Approval History
  • Table 5.15 Iclusig: Treatment Tenure
  • Table 5.16 Iclusig: Clinical Trials and Development Status
  • Table 5.17 Ibrutinib: Orphan Drug Designations
  • Table 5.18 Ibrutinib: Ongoing Clinical Trials
  • Table 5.19 Idelalisib: Clinical Trials and Development Status
  • Table 5.20 Midostaurin: Orphan Drug Designations
  • Table 5.21 Midostaurin: Clinical Trials and Development Status
  • Table 5.22 ABT-199: Clinical Trials and Development Status
  • Table 5.23 IPI - 145: Clinical Trials and Development Status
  • Table 6.1 Marketed Oral Targeted Drugs in Major Markets
  • Table 8.1 SWOT analysis of Oral Targeted Therapeutics for Leukemia
  • Table 10.1 Targeted Leukemia Drugs Market, 2013 - Split by Indication (USD Million)
  • Table 10.2 Targeted Leukemia Drugs Market, 2013 - Split by Leading Drugs (USD Million)
  • Table 10.3 Oral Targeted Leukemia Drugs Market, 2013 (USD Million)
  • Table 10.4 Targeted CML Therapeutics Market, 2013 (USD Million) - Split by Leading Drugs
  • Table 10.5 Targeted CLL Therapeutics Market, 2013 - Split by Leading Drugs (USD Million)
  • Table 10.6 Targeted ALL Therapeutics Market, 2013 - Split by Leading Drugs
  • Table 10.7 Overall Oral Targeted Leukemia Drugs Market Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Table 10.8 Overall Oral Targeted Leukemia Drugs Market Forecast, Short-Mid Term: Conservative Scenario (USD Million)
  • Table 10.9 Overall Oral Targeted Leukemia Drugs Market Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
  • Table 10.10 Overall Oral Targeted Leukemia Drugs Market Forecast, Long Term: Base Scenario (USD Million)
  • Table 10.11 Overall Oral Targeted Leukemia Drugs Market Forecast, Long Term: Conservative Scenario (USD Million)
  • Table 10.12 Overall Oral Targeted Leukemia Drugs Market Forecast, Long Term: Optimistic Scenario (USD Million)
  • Table 10.13 Gleevec Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Table 10.14 Gleevec Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
  • Table 10.15 Gleevec Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
  • Table 10.16 Gleevec Sales Forecast, Long Term: Base Scenario (USD Million)
  • Table 10.17 Gleevec Sales Forecast, Long Term: Conservative Scenario (USD Million)
  • Table 10.18 Gleevec Sales Forecast, Long Term: Optimistic Scenario (USD Million)
  • Table 10.19 Tasigna Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Table 10.20 Tasigna Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
  • Table 10.21 Tasigna Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
  • Table 10.22 Tasigna Sales Forecast, Long Term: Base Scenario (USD Million)
  • Table 10.23 Tasigna Sales Forecast, Long Term: Conservative Scenario (USD Million)
  • Table 10.24 Tasigna Sales Forecast, Long Term: Optimistic Scenario (USD Million)
  • Table 10.25 Sprycel Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Table 10.26 Sprycel Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
  • Table 10.27 Sprycel Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
  • Table 10.28 Sprycel Sales Forecast, Long Term: Base Scenario (USD Million)
  • Table 10.29 Sprycel Sales Forecast, Long Term: Conservative Scenario (USD Million)
  • Table 10.30 Sprycel Sales Forecast, Long Term: Optimistic Scenario (USD Million)
  • Table 10.31 Bosutinib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Table 10.32 Bosutinib Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
  • Table 10.33 Bosutinib Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
  • Table 10.34 Bosutinib Sales Forecast, Long Term: Base Scenario (USD Million)
  • Table 10.35 Bosutinib Sales Forecast, Long Term: Conservative Scenario (USD Million)
  • Table 10.36 Bosutinib Sales Forecast, Long Term: Optimistic Scenario (USD Million)
  • Table 10.37 Iclusig Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Table 10.38 Iclusig Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
  • Table 10.39 Iclusig Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
  • Table 10.40 Iclusig Sales Forecast, Long Term: Base Scenario (USD Million)
  • Table 10.41 Iclusig Sales Forecast, Long Term: Conservative Scenario (USD Million)
  • Table 10.42 Iclusig Sales Forecast, Long Term: Optimistic Scenario (USD Million)
  • Table 10.43 Ibrutinib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Table 10.44 Ibrutinib Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
  • Table 10.45 Ibrutinib Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
  • Table 10.46 Ibrutinib Sales Forecast, Long Term: Base Scenario (USD Million)
  • Table 10.47 Ibrutinib Sales Forecast, Long Term: Conservative Scenario (USD Million)
  • Table 10.48 Ibrutinib Sales Forecast, Long Term: Optimistic Scenario (USD Million)
  • Table 10.49 Idealisib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Table 10.50 Idealisib Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
  • Table 10.51 Idealisib Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
  • Table 10.52 Idealisib Sales Forecast, Long Term: Base Scenario (USD Million)
  • Table 10.53 Idealisib Sales Forecast, Long Term: Conservative Scenario (USD Million)
  • Table 10.54 Idealisib Sales Forecast, Long Term: Optimistic Scenario (USD Million)
  • Table 10.55 Midostaurin Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
  • Table 10.56 Midostaurin Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
  • Table 10.57 Midostaurin Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
  • Table 10.58 Midostaurin Sales Forecast, Long Term: Base Scenario (USD Million)
  • Table 10.59 Midostaurin Sales Forecast, Long Term: Conservative Scenario (USD Million)
  • Table 10.60 Midostaurin Sales Forecast, Long Term: Optimistic Scenario (USD Million)
  • Table 10.61 ABT-199 Sales Forecast, Long Term: Base Scenario (USD Million)
  • Table 10.62 ABT-199 Sales Forecast, Long Term: Conservative Scenario (USD Million)
  • Table 10.63 ABT-199 Sales Forecast, Long Term: Optimistic Scenario (USD Million)
  • Table 10.64 IPI-145 Sales Forecast, Long Term: Base Scenario (USD Million)
  • Table 10.65 IPI-145 Sales Forecast, Long Term: Conservative Scenario (USD Million)
  • Table 10.66 IPI-145 Sales Forecast, Long Term: Optimistic Scenario (USD Million)
  • Table 10.67 Prevalence of Four Main Types of Leukemia in the US, 2013
  • Table 10.68 Incidence of Leukemia in the US, 2013 and 2014
  • Table 10.69 Oral Targeted Leukemia Drugs Market in the US, 2013 - Split by Drugs (USD Million)
  • Table 10.70 Incidence of Leukemia in Japan, 2012
  • Table 10.71 Leukemia Incidence: Major European Union Countries, 2012

Listed Companies

The following companies and organizations have been mentioned in the report:

  • 1. AbbVie
  • 2. Agios Pharmaceuticals
  • 3. Akinion Pharmaceuticals
  • 4. Ambit Biosciences Corporation
  • 5. Amgen
  • 6. Apotex
  • 7. ARIAD Pharmaceuticals
  • 8. Arog Pharmaceuticals
  • 9. Ascenta Therapeutics
  • 10. Ascerta Pharma
  • 11. Ash Stevens
  • 12. Astellas Pharma
  • 13. Asterias Biotherapeutics
  • 14. AstraZeneca
  • 15. Avillion Group
  • 16. Bayer
  • 17. BDR Pharma
  • 18. BioMarin Pharmaceutical
  • 19. Boehringer Ingelheim
  • 20. Bristol-Myers Squibb
  • 21. Calithera Biosciences
  • 22. Catalent
  • 23. Celltrion
  • 24. Chroma Therapeutics
  • 25. CytRx
  • 26. Dana-Farber Cancer Institute
  • 27. Esteve Quimica
  • 28. Exelixis
  • 29. Genentech
  • 30. Genzyme
  • 31. Gilead Sciences
  • 32. GlaxoSmithKline
  • 33. Haupt Pharma
  • 34. Il-Yang Pharm. Co.
  • 35. Incyte Corporation
  • 36. Infinity Pharmaceuticals
  • 37. Inovio
  • 38. Janssen
  • 39. Jiangsu HengRui Medicine Co.
  • 40. Karyopharm Therapeutics
  • 41. Kinex Pharmaceuticals
  • 42. Lonza
  • 43. Max Foundation
  • 44. MEI Pharma
  • 45. Merck
  • 46. Millenium Pharmaceuticals
  • 47. National Institute for Health and Care Excellence
  • 48. Novartis
  • 49. OncoEthix
  • 50. Onconova Therapeutics, Inc.
  • 51. Ono Pharmaceutical Co. Ltd
  • 52. Otsuka Pharmaceutical
  • 53. Pfizer
  • 54. Pharmacyclics
  • 55. Piramal Enterprises Limited
  • 56. Plexxikon
  • 57. Portola Pharmaceuticals
  • 58. Roche
  • 59. Samsung Biologics
  • 60. Sandoz
  • 61. Sanofi
  • 62. Specialised Therapeutics Australia Pty Ltd (STA)
  • 63. Tesaro
  • 64. Teva Pharmaceuticals
  • 65. TG Therapeutics
  • 66. Tragara Pharmaceuticals, Inc.
  • 67. University of Southampton
  • 68. Wyeth
Back to Top